NasdaqGS:KNSABiotechs
Kiniksa Pharmaceuticals International (KNSA) Is Down 6.7% After Raising 2026 ARCALYST Revenue Outlook - Has The Bull Case Changed?
Earlier this month, Kiniksa Pharmaceuticals International presented at the 44th Annual J.P. Morgan Healthcare Conference and later reported that ARCALYST’s adoption as a second-line treatment for recurrent pericarditis underpinned its projection of US$900 million to US$920 million in net product revenue for 2026, supported by a cash balance of US$414.1 million and no debt.
The company also highlighted pipeline progress, including the ongoing Phase 2/3 trial for KPL-387 with data expected in...